17768199. Proteasome Inhibitors simplified abstract (Mayo Foundation for Medical Education and Research)
Contents
- 1 Proteasome Inhibitors
Proteasome Inhibitors
Organization Name
Mayo Foundation for Medical Education and Research
Inventor(s)
Asher Alban Akmal Chanan-khan of Jacksonville FL (US)
Thomas R. Caulfield of Jacksonville FL (US)
Proteasome Inhibitors - A simplified explanation of the abstract
This abstract first appeared for US patent application 17768199 titled 'Proteasome Inhibitors
Simplified Explanation
The present disclosure provides compounds of Formula (I) and Formula (II) for treating cancer.
- Compounds of Formula (I) and Formula (II) are provided for treating cancer.
- Pharmaceutical compositions containing the compounds of Formula (I) or Formula (II) are also disclosed.
- Methods of treating cancer using the compounds of Formula (I) or Formula (II) are included in the disclosure.
Potential Applications
The technology can be applied in the development of new cancer treatments using compounds of Formula (I) and Formula (II).
Problems Solved
This technology addresses the need for more effective cancer treatments by providing novel compounds for targeting cancer cells.
Benefits
The compounds of Formula (I) and Formula (II) offer potential benefits in treating cancer, potentially improving patient outcomes and quality of life.
Potential Commercial Applications
The technology could be utilized in the pharmaceutical industry for the development of new cancer therapies, leading to potential commercialization opportunities.
Possible Prior Art
Prior research may have explored similar compounds for cancer treatment, but the specific compounds of Formula (I) and Formula (II) as described in this disclosure may be novel in their structure and application.
Unanswered Questions
== How do the compounds of Formula (I) and Formula (II) compare to existing cancer treatments in terms of efficacy and safety? The article does not provide a direct comparison between the compounds of Formula (I) and Formula (II) and existing cancer treatments. Further studies or clinical trials may be needed to evaluate the efficacy and safety profile of these compounds in comparison to current standard treatments.
== What is the potential timeline for the development and approval of pharmaceutical compositions containing the compounds of Formula (I) or Formula (II) for cancer treatment? The article does not specify the timeline for the development and regulatory approval of pharmaceutical compositions containing the compounds of Formula (I) or Formula (II). Additional research, preclinical studies, and clinical trials will likely be required before these compounds can be brought to market as cancer treatments.
Original Abstract Submitted
In some embodiments, the present disclosure provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula (II) as described herein, or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising the compound of Formula (I) or Formula (II), and methods of treating cancer using the compound of Formula (I) or Formula (II) are also provided.
